Concerns & Risks -- 6/10
A "5-to-7" name. Two rubric positives are present -- China de-risked at ~2.4% of sales (well below
10%) and a clean forward P/E (~13x FY2027) modestly below the peer/industry median -- alongside a
genuinely full near-term catalyst slate (Keytruda Qlex, sac-TMT ASCO readouts, I-DXd, Winrevair,
active BD). But the single largest fact about MRK is a major, explicitly-dated regulatory overhang:
the 2028 Keytruda patent cliff compounded by IRA Medicare price-setting on the same molecule, hitting
~42% of revenue. That overhang caps the score and is why the multiple is "cheap" in the first place.
Weight: 15%
Valuation
~13x FY27
Clean P/E vs ~17x median
Below peers
Keytruda Cliff
2028 LOE
~42% of revenue at risk
Dated overhang
China Exposure
~2.4%
Down from ~6% (2024Q3)
De-risked
IRA Price-Setting
Jan 2028
Keytruda negotiated price live
Compounds LOE
Valuation -- Primary Metric: Forward P/E (FY2027)
| Metric | Estimate | Multiple | Peer Avg |
|---|---|---|---|
| P/E (FY2027 clean EPS) | ~$9.85 EPS | ~13.0x | ~15-17x (Drug Mfrs median ~17x) |
| P/E (FY2026 reported EPS) | ~$5.10 EPS* | n/m* | — |
| EV/EBITDA (TTM) | — | ~19.2x / ~11x fwd | ABBV ~16x, BMY ~8x, PFE ~7.4x |
* FY2026 reported EPS guidance ($5.04-$5.16) is contaminated by a one-time $3.62/share Cidara IPR&D charge plus a further ~$2.35/share Terns charge to come; clean operating EPS is roughly $9.80-$10. FY2027 (~$9.85 consensus, ~13x) is the real forward basis. Forward estimates sourced from company_context.md (FMP) / public.com-Zacks; flagged as not Bloomberg/VA-verified.
MRK trades at ~13x clean FY2027 P/E -- below the drug-manufacturers median (~17x)
and below its own 5-yr norm, but roughly in line with peers carrying large patent cliffs (ABBV). Not
a screaming-cheap 8x like PFE/BMY, nor expensive. Modestly below peer average on a clean-earnings
basis -- which the rubric rewards -- but the discount is the market pricing the Keytruda cliff, not a free lunch.
China Exposure -- Already De-Risked
China is now ~2.4% of revenue and falling -- already de-risked.
Gardasil drove the collapse: ex-FX Gardasil sales fell -40% (2025Q1), -55% (2025Q2), and -22%
(2026Q1) on weak China/Japan HPV demand. The bad news is largely in the base; China is no longer a
swing factor. Comfortably below 10% -- rubric-positive.
Key catalysts
| # | Catalyst | Detail |
|---|---|---|
| 1 | Keytruda Qlex (subcutaneous) | Launched, $128M in 2026Q1, permanent J-code effective Apr 1, 2026. Key tool to retain patient loyalty ahead of IV biosimilars. Keytruda family still +8% ex-FX in 1Q26. |
| 2 | sac-TMT (TROP2 ADC, Kelun) | 17 Phase III studies, 13 first-mover; OptiTROP-Breast05 and lung readouts at ASCO 2026. Major near-term clinical catalyst. |
| 3 | I-DXd (Daiichi ADC) | FDA priority review granted for 2L+ extensive-stage small-cell lung cancer -- near-term approval catalyst. |
| 4 | Winrevair (PAH) ramp | Global sales ~$525M/qtr, >1,600 new U.S. patients/qtr, OUS launches ramping -- durable growth driver. Enlicitide (oral PCSK9) adds large-market launch optionality. |
| 5 | Active BD cadence | Cidara (closed, antiviral) and Terns (CML, TERN-701, closing soon). Management keeps BD a "high priority." Pipeline-replenishment ahead of the cliff. |
Regulatory / Political risk -- the real overhang
| # | Risk | Severity | Detail |
|---|---|---|---|
| 1 | Keytruda U.S. Patent Cliff | HIGH | Composition-of-matter patent expires end-2028; ~42% of revenue ($29B+ in 2024) faces biosimilar erosion. Largest pharma patent cliff in history; biosimilars in late-stage dev at Celltrion, Samsung Bioepis, Amgen. |
| 2 | IRA Medicare Price-Setting | HIGH | Keytruda selected for negotiation; negotiated price live Jan 2028 -- compounds the LOE on the same molecule. Januvia faces a ~79% Medicare cut in 2026. |
| 3 | Post-Cliff Pipeline Execution | MEDIUM | Nothing replaces $29B individually; the thesis rests on a portfolio of probabilistic launches (sac-TMT, I-DXd, enlicitide, Winrevair) plus BD, judged only at 2027+ readouts. |
| 4 | Tariff / Drug-Pricing Politics | MEDIUM | Ongoing pharma-tariff and drug-pricing political noise; sector-wide headwind rather than MRK-specific. |
| 5 | China / Gardasil Single-Country | LOW | Largely already in the base -- China down to ~2.4% of revenue. No longer a swing factor. |
Bull case
| # | Factor | Detail |
|---|---|---|
| 1 | China Already Collapsed | Now immaterial at ~2.4% of sales; the Gardasil-China shock is in the base, not ahead of it. |
| 2 | Cheap on Clean Earnings | ~13x clean FY2027 P/E, below the drug-manufacturers median (~17x). The multiple already discounts the cliff. |
| 3 | Diversifying Launch Portfolio | Winrevair, Capvaxive, Welireg, Keytruda Qlex, sac-TMT, enlicitide, I-DXd visibly broadening the revenue base ahead of 2028. |
| 4 | Sentiment Can Invert | As post-2028 durability gets proven, the worse-to-better sentiment shift is the upside path the discount ignores. |
| 5 | Oligopoly + Management | Dominant, price-setting franchises (Keytruda, Gardasil) run by a stable team with an ~86% promise hit-rate. |
Bear case
| # | Factor | Detail |
|---|---|---|
| 1 | 2028 Double-Cliff | ~42% of revenue (Keytruda) hits a hard patent + IRA double-cliff in 2028 -- the single largest fact about the name. |
| 2 | No Single Replacement | Nothing in the pipeline replaces $29B individually; the thesis rests on a portfolio of probabilistic launches. |
| 3 | EPS Masked by BD Charges | FY2026 reported EPS is buried under one-time BD charges (Cidara, Terns), masking underlying dilution from serial deals. |
| 4 | "Cheap" Could Be a Trap | The 13x is a value trap if post-cliff revenue cannot stay flat-to-up; the discount reflects a real, dated risk. |
| 5 | No Near-Term Resolution | No catalyst resolves the central 2028 question before then; FCF also fell -32% in FY2025 (quality-gate NO). |
Score rationale
Score of 6/10 reflects a "5-to-7" name: real rubric positives offset by a major, explicitly-dated regulatory overhang that caps the score.
What supports the score: China de-risked at ~2.4% of sales (well below 10%) (+1). Clean ~13x FY2027 P/E modestly below the peer/industry median (~17x) (+1). A genuinely full near-term catalyst slate -- Keytruda Qlex ramp, sac-TMT ASCO readouts, I-DXd, Winrevair, active BD (+1). Oligopoly-protected, price-setting franchises run by a high-quality team (+1).
Why not higher: The single largest fact about MRK is a major, explicitly-dated regulatory overhang -- the 2028 Keytruda patent cliff compounded by IRA Medicare price-setting on the same molecule, hitting ~42% of revenue. That is precisely the rubric's score-capping condition, and it is why the multiple is "cheap" in the first place. FY2026 reported EPS is masked by one-time BD charges, and FCF fell -32% in FY2025.
Net: A classic sentiment-inversion candidate (de-risked China + discounted multiple + diversifying launches), but the burden of proof on post-cliff durability keeps it out of the top tier. The discount is the market pricing a real, dated risk -- not a free lunch.
Data sourced from Daloopa, company filings, earnings transcripts, and public web sources. Forward consensus (FMP/public.com-Zacks) flagged as not Bloomberg/VA-verified.